Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | KTN0073-IgG1 |
Synonyms | |
Therapy Description |
KTN0073-IgG1 is a chimeric anti-MET antibody comprised of a rodent variable region and human IgG1 region, which inhibits phosphorylation of MET and induces MET degradation, potentially resulting in decreased proliferation of tumor cells harboring wild-type or mutant MET (PMID: 27550450). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KTN0073-IgG1 | MET Antibody 28 MET Inhibitor 59 | KTN0073-IgG1 is a chimeric anti-MET antibody comprised of a rodent variable region and human IgG1 region, which inhibits phosphorylation of MET and induces MET degradation, potentially resulting in decreased proliferation of tumor cells harboring wild-type or mutant MET (PMID: 27550450). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|